

RESEARCH

Open Access



A novel multidimensional strategy to evaluate *Belamcanda chinensis* (L) DC and *Iris tectorum* Maxim based on plant metabolomics, digital reference standard analyzer and biological activities evaluation

Hongxu Zhou^{1,2†}, Yi Zhang^{2†}, Hui Liang¹, Huijie Song¹, Jiaming Zhao¹, Li Liu¹, Jun Zeng², Lei Sun³, Shuangcheng Ma^{3*} and Dali Meng^{1*} 

Abstract

Background: *Belamcanda chinensis* (L.) DC. (BC) belongs to the family of *Iridaceae* and is widely cultivated and used in many Chinese patent medicine and Chinese medicinal formulae. However, due to the high similarities in appearance such as color and shape to *Iris tectorum* Maxim (ITM), another plant from the same family, BC is often confused or even misused with ITM.

Methods: Therefore, in order to distinguish the chemical constituents, qualities and biological activities of BC and ITM, multiple technologies including plant metabolomics, digital reference standard (DRS) analyzer and biological activities assay were employed to provide a sufficient basis for their practical applications.

Results: In plant metabolomics, the PCA and OPLS-DA score plot indicated the obvious differences in chemical profiling between BC and ITM and 6 compounds were successfully identified to contribute to the differences. In DRS study, the fingerprints of 10 and 8 compounds in BC and ITM were developed based on DRS analyzer, respectively, involving relative retention time (RRT) method and linear calibration using two reference substances (LCTRS) technique. The DRS analyzer also accurately identified 10 and 8 compounds from BC and ITM, respectively, by using only two reference standards. In biological activities assay, BC had a better anticancer effect than ITM due to the high abundance of irigenin, while ITM showed stronger hepatoprotective activity than BC because of the high abundance of tectoridin.

Conclusions: Therefore, due to the significant differences of *B. chinensis* and *I. dichotoma* in chemical composition and biological activities, the current studies strongly proved that these two medicinal plants could not be mixed in industrial production and clinical medication.

*Correspondence: masc@nifdc.org.cn; mengdali@syphu.edu.cn

†Hongxu Zhou and Yi Zhang contributed equally

¹ School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China

³ National Institutes for Food and Drug Control, Beijing 100050, People's Republic of China

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Keywords: *Belamcanda chinensis* (L.) DC, *Iris tectorum* Maxim, Plant metabolomics, Digital reference standard, Biological activities

Background

Belamcanda chinensis (L.) DC. (BC), a perennial herbaceous plant whose rhizome is named as *She-gan* in a traditional Chinese medicine (TCM) belongs to the family of *Iridaceae* and is widely cultivated in China, Korea, Japan, India and eastern Russia as an economic medicinal plant. *She-gan* has been used in many Chinese patent medicine and Chinese medicinal formulae such as Xiaoe Qingre granules, Xiaoe Qingfei oral liquid, and Shengan Liyan oral liquid, etc., for the treatment coughing and pharyngitis.

However, *Chuan-she-gan*, the rhizome of *Iris tectorum* Maxim (ITM), another medicinal plant comes from the family of *Iridaceae* mainly distributing in Sichuan of China, is also used for the treatment of asthma, cough, tonsillitis and pharyngitis. Actually, both of these two medicinal plants are rich in isoflavonoids, stilbenes, xanthones, and simple phenols [1–3]. Among them, isoflavones, such as tectoridin, iridin, tectorigenin, irigenin, irisfloreantin and so on [3–5], are the major bioactive constituents of two medicines that have shown a wide range of biological activity, such as anticancer, hepatoprotective, antiatherosclerosis, antiosteoporosis and antihyperlipidemic, etc. [1, 6–8].

Consequently, in the medicinal market, as well as in the pharmaceutical industry, because of the high similarities in appearance such as color and shape between BC and ITM, they were often confused or even mixed with each other when used for the treatments of coughing and pharyngitis. Therefore, it is very necessary to distinguish these two plants from their chemical constituents and biological activities by multiple technologies and approaches, so as to provide a sufficient basis and guidance for their industrial production and clinical medication.

Metabolomics, genomics, and proteomics are important components of system biology. As an important branch of metabolomics, plant metabolomics describes the alterations in the content and composition of different plant phytochemicals [9]. Currently, the most promising technique in terms of metabolome coverage is ultra-high-performance liquid chromatography-high resolution tandem mass spectrometry (UHPLC-HRMS/MS), which is a powerful analytical tool for the analysis of the known compounds and elucidation of unknown compounds in herbal medicines. Here, UHPLC-Q Exactive-HRMS/MS based untargeted metabolomics techniques

were used for qualitative studies to distinguish BC and ITM.

Quality control analysis of TCM is important for safe and effective use. The reference standard is the most important role for qualitative and quantitative analysis of TCM. There is an increasing demand for reference standards with the development of TCM quality control. At the same time, some TCM compounds are difficult to be extracted, isolated, and purified, led to a significant increase in the cost of TCM analysis. Linear calibration using two reference substances (LCTRS) approaches, a substitute reference standard method, can deal with the above problems effectively [10–12]. LCTRS is a method for the qualitative determination of several compounds to be measured by two reference standards by using several constant eigenvalues and algorithms. The principle of LCTRS is that there is a linear relationship between the retention time (t_R) of the compounds on two different HPLC systems (including chromatographs and columns). The method has been successfully developed for the quality analysis of *Salvia miltiorrhiza*, *Paris polyphylla*, *Rheum officinale* [10–12]. Relative retention time (RRT) technique, a qualitative substitute reference standard method, can qualitative determination of several compounds to be measured by one reference standard. Finally, we introduced the concept of the digital reference standard (DRS), which supports the chromatographic algorithm methods of RRT and LCTRS. In the present study, quality control methods of fingerprint involving 10 compounds of BC and 8 compounds of ITM respectively were developed based on DRS method.

Recently, several studies on the quality control of BC were reported. Li et al. [13] evaluated the quality of BC by the establishment of chromatographic fingerprinting profile employing HPLC–DAD–MS method and simultaneous determination of seven phenol compounds. Chen et al. [14] reported the spatial chemical profiles of BC at different growth ages from various origins through qualitative and quantitative analyses by using UHPLC–Q/TOF–MS and UHPLC–QqQ–MS. Wen et al. [15] used a chemical profiling method to evaluate the quality of BC and compare the chemical compositions by HPLC analysis combining with multivariate data analysis. However, these methods only focused on one or several marker compounds and failed to distinguish these two plants from their chemical constituents and biological activities. Herein, the systematic studies on the chemical constituents, qualities and biological activities of BC and ITM

Table 1 The sorts of *Belamcanda chinensis* (L.) DC and *Iris tectorum* Maxim

No.	Species	Location	Collection time
BC01	<i>B. chinensis</i>	Anguo, Hebei	April 2020
BC02	<i>B. chinensis</i>	Baoding, Hebei	April 2020
BC03	<i>B. chinensis</i>	Yuncheng, Henan	April 2020
BC04	<i>B. chinensis</i>	Qinhuangdao, Hebei	April 2020
BC05	<i>B. chinensis</i>	Nangong, Hebei	May 2020
BC06	<i>B. chinensis</i>	Yuncheng, Shanxi	May 2020
ITM01	<i>I. tectorum</i>	Chengdu, Sichuan	April 2020
ITM02	<i>I. tectorum</i>	Chengdu, Sichuan	April 2020
ITM03	<i>I. tectorum</i>	Chengdu, Sichuan	May 2020
ITM04	<i>I. tectorum</i>	Chengdu, Sichuan	May 2020
ITM05	<i>I. tectorum</i>	Baoding, Hebei	May 2020
ITM06	<i>I. tectorum</i>	Guiyang, Guizhou	April 2020
ITM07	<i>I. tectorum</i>	Bozhou, Anhui	April 2020

were carried out by plant metabolomics, digital reference standard analyzer and biological activities assay.

Methods

Collection of plant materials

The rhizomes of two original medicinal plants of *Belamcanda chinensis* (L.) DC and *Iris tectorum* Maxim were collected from different habitats in China, and dried at room temperature. All of them were identified by

Table 2 Information of columns

No.	Brand	Type	Specification
Column 1	Osaka Soda	Capcell pak C ₁₈	250 × 4.6 mm, 5 μm
Column 2	Dikma	Diamonsil C ₁₈	250 × 4.6 mm, 5 μm
Column 3	Phenomenex	Luna C ₁₈	250 × 4.6 mm, 5 μm
Column 4	TechMate	TechMate C ₁₈	250 × 4.6 mm, 5 μm
Column 5	FLM	Titank C ₁₈	250 × 4.6 mm, 5 μm
Column 6	Waters	Symmetry C ₁₈	250 × 4.6 mm, 5 μm
Column 7	Waters	SunFire C ₁₈	250 × 4.6 mm, 5 μm
Column 8	AkzoNobel	Kromasil 100-5-C ₁₈	250 × 4.6 mm, 5 μm
Column 9	Agilent	ZORBAX Eclipse Plus C ₁₈	250 × 4.6 mm, 5 μm
Column 10	SHIMADZU	Shim-pack GIST C ₁₈	250 × 4.6 mm, 5 μm
Column 11	Exmere Ltd	Exsil Mono 100 C ₁₈	250 × 4.6 mm, 5 μm
Column 12	SHIMADZU GL	Inertsil ODS-3 C ₁₈	250 × 4.6 mm, 5 μm
Column 13	Dikma	Inspire C ₁₈	250 × 4.6 mm, 5 μm
Column 14	Agilent	ZORBAX Eclipse XDB C ₁₈	250 × 4.6 mm, 5 μm
Column 15	Agilent	ZORBAX SB C ₁₈	250 × 4.6 mm, 5 μm
Column 16	Agilent	5 HC C ₁₈	250 × 4.6 mm, 5 μm
Column 17	Agilent	5 TC C ₁₈	250 × 4.6 mm, 5 μm
Column 18	YMC	Pack ODS-A	250 × 4.6 mm, 5 μm
Column 19	ZHONGPU	RP-C ₁₈	250 × 4.6 mm, 5 μm
Column 20	SVEA	C ₁₈ Opal	250 × 4.6 mm, 5 μm

Table 3 The gradient elution conditions of the mobile phase

Time (min)	Phase A (%)	Phase B (%)	Phase C (%)
0–15	5–17	0–83	95–0
15–24	17–20	83–80	0
24–48	20–24	80–76	0
48–52	24–28	76–72	0
52–60	28–31	72–69	0
60–65	31–35	69–65	0
65–80	35–70	65–30	0
80–81	70–5	30–0	0–95
81–90	5	0	95

Professor Yi Zhang. Their sample number, species, habitats and collection time were listed in Table 1.

Chemicals and reagents

Chromatography-grade acetonitrile and methanol were purchased from Fisher Chemical (CA, USA). MS-grade ammonium acetate, formic acid, acetonitrile and methanol were obtained from Fisher Chemical (CA, USA). Chromatography grade phosphoric acid and ethanol were purchased from Sinopharm Chemical Reagent (Shanghai, China). Methyl-β-cyclodextrin (Me-β-CD) was obtained from Aladdin Co., Ltd (Shanghai, China). The water used was produced by Milli-Q system (Millipore, Bedford, MA, USA). Tectoridin, bicyclol and iriflorentine were purchased from National Institutes for Food and Drug Control (NIFDC, Beijing, China). Iristectorin A and iristectorigenin-A-7-glucoside were obtained from Nature Standard Technical Service Co., Ltd (Shanghai, China). Irirogenin 7-glucoside was purchased from Chengdu Push Bio-technology Co., Ltd (Chengdu, China). Tectorigenin was obtained from Chengdu Puruifa Technology Co., Ltd (Chengdu, China). Iristectorigenin B, 3',6-dimethoxy-4',5,7-trihydroxyisoflavone, 5,7-dihydroxy-3-(3-hydroxy-4,5-dimethoxyphenyl)-6-methoxy-4-benzopyrone and 5,3-dihydroxy-4,5-dimethoxy-6,7-methylenedioxyisoflavone were purchased from Shanghai Tongtian Biotechnology Co., Ltd (Shanghai, China). Oxaliplatin was obtained from Oxaliplatin, Hospira Inc., (IL, Australia). D-galactosamine, curcumin, cell counting kit-8, RPMI1640 medium and DMEM high glucose culture medium were purchased from Meilun Biotechnology Co., Ltd (Dalian, China).

Standard solutions and sample preparation for LC-HR/MS metabolomics and DRS study

The dry powder (0.1 g) of BC and ITM were extracted with 25 mL of 70% ethanol in an ultrasonic bath for 60 min. The supernatant was filtered through a 0.22 μm

Table 4 Chemical characterization of *B. chinensis* (BC) and *I. tectorum* (ITM) by UHPLC-Q-exactive-MS/MS in positive ion

Peaks	Retention time (min)	<i>m/z</i> Quasi-molecular [M + H] ⁺	<i>m/z</i> Calculated [M + H] ⁺	Error (ppm)	Formula	MS/MS fragments	Identification	Reference	Source
P1	5.13	423.0919	423.0922	- 7.09	C ₁₉ H ₁₈ O ₁₁	405, 333, 305, 303, 275	Mangiferin	[14, 18–20]	BC, ITM
P2	5.35	423.0919	423.0922	- 7.09	C ₁₉ H ₁₈ O ₁₁	405, 333, 305, 303, 275	Isomangiferin	[14, 18, 20]	BC, ITM
P3	5.35	437.1087	437.1078	20.59	C ₂₀ H ₂₀ O ₁₁	315, 303, 301, 279, 227	7-O-Methylmangiferin	[14, 18]	BC
P4	5.49	625.1762	625.1763	- 1.60	C ₂₈ H ₃₂ O ₁₆	463, 340, 303, 279, 227	Tectorigenin-7-O-glucosyl-4'-O-glucoside	[14, 18, 19, 21]	BC, ITM
P5	6.95	625.1760	625.1763	- 4.80	C ₂₈ H ₃₂ O ₁₆	540, 510, 463, 437, 315, 301	Tectorigenin-7-O-β-glucosyl (1–6) glucoside	[14, 18, 20]	BC, ITM
P6	7.93	463.1232	463.1235	- 6.48	C ₂₂ H ₂₂ O ₁₁	301, 286	Tectoridin ^a	[14, 18–20]	BC, ITM
P7	8.45	493.1345	493.1341	8.11	C ₂₃ H ₂₄ O ₁₂	463, 331, 316, 307, 229	Iristectorin A ^a	[14, 18, 20]	BC, ITM
P8	8.52	479.119	479.1184	12.52	C ₂₂ H ₂₂ O ₁₂	331, 317, 287	3'-Hydroxytectoridin	[14, 18, 20]	BC, ITM
P9	8.99	493.1347	493.1341	12.17	C ₂₃ H ₂₄ O ₁₂	331, 314, 279, 261, 199, 154	Iristectorin B ^a	[14, 18–20]	BC, ITM
P10	9.19	523.1381	523.1373	15.29	C ₂₄ H ₂₆ O ₁₃	361, 340	Iridin ^a	[14, 18, 20]	BC, ITM
P11	9.19	523.1441	523.1446	- 9.56	C ₂₄ H ₂₆ O ₁₃	361, 340, 279, 227, 199, 154, 142	Iridinisomer	[14, 18, 20]	BC, ITM
P12	10.6	535.1435	535.1446	- 20.56	C ₂₅ H ₂₆ O ₁₃	421, 377, 336, 315	3',5'-Dimethoxyirisolone-4'-O-β-D-glucoside	[14, 18, 20]	BC
P13	11.84	301.0706	301.0707	- 3.32	C ₁₆ H ₁₂ O ₆	286, 231, 154, 142	Tectorigenin ^a	[14, 18, 20]	BC, ITM
P14	12.05	673.1777	673.1763	20.80	C ₃₂ H ₃₂ O ₁₆	643, 615, 515, 361, 301	6''-O-vanilloyliridin	[14, 18]	BC
P15	12.18	331.0798	331.0812	- 42.29	C ₁₇ H ₁₄ O ₇	316, 303, 279, 254, 234	Iristectorigenin B ^a	[14, 18–20]	BC, ITM
P16	12.43	331.0796	331.0812	- 48.33	C ₁₇ H ₁₄ O ₇	316, 303, 279, 254, 234	Iristectorigenin A ^a	[14, 18, 20]	BC, ITM
P17	12.51	361.0912	361.0918	- 16.62	C ₁₈ H ₁₆ O ₈	346, 331, 183	Irigenin ^a	[14, 18, 20]	BC, ITM
P18	12.82	373.0919	373.0918	2.68	C ₁₉ H ₁₆ O ₈	361, 331, 301, 279, 226	Noririsfloreantin	[14, 18]	BC
P19	13.69	299.0549	299.055	- 3.34	C ₁₆ H ₁₀ O ₆	228, 199, 169, 154	Irilone	[14, 18–19]	BC, ITM
P20	14.00	387.1071	387.1074	- 7.75	C ₂₀ H ₁₈ O ₈	359, 329, 262	Irisfloreantin ^a	[14, 18–20]	BC
P21	14.06	359.0765	359.0761	11.14	C ₁₈ H ₁₄ O ₈	329, 299, 271, 248, 223	Dichotomitin ^a	[14, 18–20]	BC

^a Authentic standards

membrane filter before analysis. All reference chemicals were dissolved in 70% ethanol at 1.0 mg mL⁻¹ as stock solutions. These stock solutions were stable for at least 1 week at room temperature. A defined amount of the above stock solutions were mixed and diluted to an appropriate concentration as the standard stock solution: these standards were stable at least for 2 weeks under 4 °C.

Plant metabolomics with liquid chromatography/high-resolution mass spectrometry (LC-HR/MS) analysis

The analyses were performed on an Ultimate 3000 UHPLC system coupled to Q Exactive MS (Thermo Fisher Scientific, CA, USA). UHPLC analyses were performed on a Waters Acquity UPLC BEH C₁₈ column (2.1 × 100 mm, 1.7 μm; Waters Technologies, MA, USA) and Waters Van Guard BEH C₁₈ column (2.1 × 5 mm, 1.7 μm; Waters Technologies, MA, USA). The mobile phase was consisted of (A) 0.1% formic acid–water and (B) acetonitrile, and the gradient program was optimized

Table 5 Chemical characterization of *B. chinensis* (BC) and *I. tectorum* (ITM) by UHPLC-Q-exactive-MS/MS in negative ion

Peaks	Retention time (min)	<i>m/z</i> Quasi-molecular [M-H] ⁻	<i>m/z</i> Calculated [M-H] ⁻	Error (ppm)	Formula	MS/MS fragments	Identification	Reference	Source
N1	3.6	535.166	535.1668	- 14.95	C ₂₁ H ₃₀ O ₁₃	525, 489, 323, 235, 215	Tectoruside	[3, 19]	BC, ITM
N2	3.96	583.1314	583.1305	15.43	C ₂₅ H ₂₈ O ₁₆	535, 489, 403, 352, 307, 273	Neomangiferin	[3, 18, 19]	BC
N3	4.23	373.1141	373.114	2.68	C ₁₅ H ₂₀ O ₈	363, 273, 235, 215	Androsin	[3, 19]	BC, ITM
N4	5.12	421.078	421.0776	9.50	C ₁₉ H ₁₈ O ₁₁	364, 327, 307, 273, 235, 215	Mangiferin	[3, 18, 19]	BC, ITM
N5	5.35	421.0779	421.0776	7.12	C ₁₉ H ₁₈ O ₁₁	395, 333, 307, 273, 255, 235, 215	Isomangiferin	[3, 18]	BC, ITM
N6	6.40	435.0923	435.0933	- 22.98	C ₂₀ H ₂₀ O ₁₁	377, 339, 307, 275, 235, 215	7-O-methylmangiferin	[3, 18]	BC
N7	6.50	447.0926	447.0933	- 15.66	C ₂₁ H ₂₀ O ₁₁	327, 313, 285, 235, 215	Luteolin-6-C-β-D-glucoside	[3, 22]	BC, ITM
N8	6.93	435.0925	435.0933	- 18.39	C ₂₀ H ₂₀ O ₁₁	391, 352, 313, 275, 235, 215	7-O-methylisomangiferin	[3, 18]	BC
N9	6.95	623.1622	623.1618	6.42	C ₂₈ H ₃₂ O ₁₆	567, 537, 435, 313, 299, 284, 235, 215	Tectorigenin-7-O-glucosyl-4'-O-glucoside	[3, 23]	BC, ITM
N10	7.11	463.1246	463.1246	0.00	C ₂₂ H ₂₄ O ₁₁	327, 273, 235, 215	Dihydrokaempferol-7-O-glucoside	[3, 23]	ITM
N11	7.37	653.1712	653.1723	- 16.84	C ₂₉ H ₃₄ O ₁₇	595, 509, 403, 329, 243	Iristectorigenin-A-7-O-β-glucosyl (1 → 6)-glucoside	[3, 18, 19]	BC
N12	7.57	431.0973	431.0984	- 25.52	C ₂₁ H ₂₀ O ₁₀	431, 269, 235, 215	Saponaretin	[3, 22]	BC, ITM
N13	7.57	477.1029	477.1038	- 18.86	C ₂₁ H ₂₀ O ₁₀	431, 269, 235	Genistein-7-O-glucoside	[3, 24]	BC, ITM
N14	7.92	461.1087	461.1089	- 4.34	C ₂₂ H ₂₂ O ₁₁	299	Tectoridin ^a	[3, 18]	BC, ITM
N15	7.92	461.1087	461.1089	- 4.34	C ₂₂ H ₂₂ O ₁₁	413, 352, 329, 299, 284, 255	Tectorigenin-4'-O-β-D-glucoside	[3, 18]	BC, ITM
N16	7.92	507.1147	507.1144	5.92	C ₂₂ H ₂₂ O ₁₁	461, 299	Isotectorigenin-7-O-β-D-glucoside	[3, 18]	BC, ITM
N17	8.01	593.1499	593.1512	- 21.92	C ₂₇ H ₃₀ O ₁₅	507, 461, 299	Genistein-7-Ogentiobioside	[3, 25]	BC
N18	8.21	447.0925	447.0933	- 17.89	C ₂₁ H ₂₀ O ₁₁	352, 317, 273, 235, 215	Orobol-7-O-D-glucoside	[3, 24]	BC
N19	8.43	491.1202	491.1195	14.25	C ₂₃ H ₂₄ O ₁₂	329, 314, 227, 215	Iristectorin A ^a	[3, 18, 19]	BC, ITM
N20	8.99	491.1201	491.1195	12.22	C ₂₃ H ₂₄ O ₁₂	329, 314, 227, 215	Iristectorin B ^a	[3, 18, 19]	BC, ITM
N21	9.19	521.1293	521.1301	- 15.35	C ₂₄ H ₂₆ O ₁₃	427, 359, 344	Iridin ^a	[3, 18]	BC, ITM
N22	9.19	567.1348	567.1355	- 12.34	C ₂₄ H ₂₆ O ₁₃	521, 507, 359, 344	Isoiridin	[3, 18]	BC, ITM
N23	9.83	257.0815	257.0819	- 15.56	C ₁₅ H ₁₄ O ₄	246, 230, 215	Gnetucleistol D	[3]	BC, ITM
N24	11.57	653.1708	653.1723	- 22.96	C ₂₉ H ₃₄ O ₁₇	326, 299, 269	Iristectorin-B-4'-O-glucoside	[3, 18]	ITM
N25	11.68	519.113	519.1144	- 26.97	C ₂₄ H ₂₄ O ₁₃	326, 268, 230	Dichotomitin-3'-O-glucoside	[3, 18, 19]	BC, ITM
N26	11.84	299.0557	299.0561	- 13.38	C ₁₆ H ₁₂ O ₆	284, 268, 242, 230, 215, 195	Tectorigenin ^a	[3, 18, 19]	BC, ITM
N27	12.02	641.151	641.1512	- 3.12	C ₃₁ H ₃₀ O ₁₅	459, 299	6''-O-phydroxybenzoyliridin	[3, 18]	BC, ITM
N28	12.04	671.1599	671.1618	- 28.31	C ₃₂ H ₃₂ O ₁₆	641, 613, 359, 326, 299	6''-O-vanilloyliridin	[3, 18]	BC, ITM
N29	12.18	329.0667	329.0667	0.00	C ₁₇ H ₁₄ O ₇	315, 286, 268, 242	Iristectorigenin B ^a	[3, 18, 19]	BC, ITM
N30	12.43	329.0667	329.0667	0.00	C ₁₇ H ₁₄ O ₇	315, 286, 268, 242, 198	Iristectorigenin A ^a	[3, 18]	BC, ITM
N31	12.46	301.0715	301.0718	- 9.96	C ₁₆ H ₁₄ O ₆	280, 273, 242, 215	Dihydrokaempferide	[3, 23]	BC, ITM
N32	12.51	359.0763	359.0772	- 25.06	C ₁₈ H ₁₆ O ₈	344, 329, 181	Irigenin ^a	[3, 18]	BC, ITM
N33	13.66	297.0406	297.0405	3.37	C ₁₆ H ₁₀ O ₆	280, 258, 230, 215	Irilone	[3, 18, 19]	BC, ITM
N34	13.68	343.0822	343.0823	- 2.91	C ₁₈ H ₁₆ O ₇	318, 297, 280	Dalspinoin	[3]	BC, ITM
N35	13.94	327.0511	327.051	3.06	C ₁₇ H ₁₂ O ₇	294, 258, 230	Iriflogenin	[3]	BC, ITM

Table 5 (continued)

Peaks	Retention time (min)	<i>m/z</i> Quasi-molecular [M-H] ⁻	<i>m/z</i> Calculated [M-H] ⁻	Error (ppm)	Formula	MS/MS fragments	Identification	Reference	Source
N36	13.94	373.0919	373.0929	- 26.80	C ₁₉ H ₁₈ O ₈	336, 294, 280, 258, 230, 215	Junipegenin C	[3, 18]	BC
N37	14.04	357.0607	357.0616	- 25.21	C ₁₈ H ₁₄ O ₈	294, 230	Dichotomitin ^a	[3, 18, 19]	BC

^a Authentic standards

as follows: 0–1 min, 5% B; 1–9 min, 5–25% B; 9–19 min, 25–75% B; 19–25 min, 75–100% B; 25–26 min 100–5% B, 26–30 min 5% B. The column temperature was set at 45 °C. The injection volume was 1 µL. The flow rate was set at 0.4 mL min⁻¹. The MS analysis of lipids was carried out on Q Exactive under the conditions: full MS/ddMS² mode; evaporation temperature, 350 °C; capillary temperature, 320 °C; spray voltage, 3.0 kV for negative ion mode and 3.5 kV for positive ion mode; aux gas flow rate (arb), 10; sheath gas rate (arb), 35; mass range (*m/z*), 100–1500.

DRS study with instruments and chromatographic conditions

Chromatographic analysis was performed on Agilent 1260 high-performance liquid chromatography with a DAD detector (Agilent Technologies, CA, USA) and Waters e2695 high-performance liquid chromatography with a 2998 PDA detector (Waters Technologies, MA, USA). Twenty-four columns (Table 2) from mainstream manufacturers were randomly selected. DRS method research is recommended to use at least ten columns from three manufacturers.

The main constituents of *B. chinensis* and *I. tectorum* are iristectorigenin A, iristectorigenin B, and irigenin. Because of the high similarity in their chemical constituents (Appendix Fig. 8), it is difficult to separate these three compounds by conventional HPLC method. Previous study found that methyl-β-cyclodextrin (Me-β-CD) could successfully resolve these problems and the resolution of the other components could also meet the content determination requirements [16]. Thus, Me-β-CD is used to the mobile phase additive. Mobile phase A was acetonitrile, mobile phase B was 0.1% phosphoric acid and 0.55% Me-β-CD-water and mobile phase C was 0.1% phosphoric acid–water. The elution procedure was shown in Table 3. The detection wavelength was 266 nm, and the UV–Vis absorption spectra (210–600 nm) were collected. The column temperature was 35 °C, the flow rate was 1 mL min⁻¹, and the injection volume was 10 µL.

Data processing

The raw LC-HRMS data files (.raw) were uploaded to the XCMS web version platform (<https://xcmsonline.scripps.edu/>) for retention time alignment, peak picking, and annotation [17]. The chromatographic peak data were normalized uniformly, and the multidimensional data were further analyzed by the SIMCA-P software 14.1 (Umetrics, Umea, Sweden) for multivariate data analysis by principal components analysis (PCA), orthogonal partial least squares-discriminant analysis (OPLS-DA).

Evaluation of in vitro bioactivities


All compounds (tectoridin, iridin, tectorigenin, iristectorigenin B, iristectorigenin A, irigenin, irisfloreline, dichotomitin), BC 70% ethanol extract and ITM 70% ethanol extract were evaluated for their cytotoxicity against HepG2 and A549 cell lines using cell counting kit-8 (CCK-8) methods. Simultaneously, all standard compounds and ethanol extracts were evaluated for their hepatoprotective activities in BRL-3A and L02 cell lines as well as neuroprotective activities in BV2 cells in vitro.

Cell culture

HepG2, A549, BRL-3A, L02 and BV2 cell lines were obtained from Shenyang Pharmaceutical University. Cells were cultured in appropriate medium (DMEM or RPMI1640) supplemented with 10% FBS, 1% penicillin/streptomycin and 5% CO₂ at 37 °C.

Toxicity measurements

The cytotoxicity against HepG2 and A549 cells of 8 compounds, BC and ITM ethanol extracts were determined by CCK-8 assay. Briefly, 1 × 10⁴ cells were placed into each well of a 96-well plate and preincubated for 24 h in cell culture incubator (37 °C, 5% CO₂). Secondly, cells were treated with different concentrations of 8 compounds (100–0.7813 µM), BC and ITM ethanol extracts (6400–25 µg mL⁻¹) for 24 h, respectively. Then, cell viability was measured by cell counting kit-8 (CCK-8) assay (Dalian Meilun Biotechnology, Dalian, China) according to the manufacturer's instructions. The absorbance values at 450 nm (OD450) were observed by Tecan Spark 10 K microplate reader (Tecan, Mannedorf, Switzerland).




The viability of the control group is defined as 100%. Oxaliplatin was tested as a positive control.

Hepatoprotective and neuroprotective assay

Eight compounds and 2 ethanol extracts were evaluated for their hepatoprotective activities against D-galactosamine induced L02 cell injury in vitro. The neuroprotective effects were determined by BV2 cells. The cells were maintained in an appropriate medium (DMEM

or RPMI1640, Dalian Meilun Biotechnology, Dalian, China) in a humidified atmosphere of 5% CO₂ at 37 °C. The cells were seeded into 96-well plates at a density of 1 × 10⁵ cells mL⁻¹. After attachment, the cells were pre-treated with the test compounds and extracts in different concentrations for 2 h. D-galactosamine (25 mM) or LPS solution (10 μg mL⁻¹) was subsequently added for incubating another 24 h. Then, cell viability was measured by cell counting kit-8 (CCK-8) assay (Dalian Meilun




Biotechnology, Dalian, China) according to the manufacturer’s instructions. The absorbance values at 450 nm (OD450) were observed by Tecan Spark 10 K microplate reader (Tecan, Mannedorf, Switzerland). The viability of the control group is defined as 100%. Bicyclol and curcumin was tested as a positive control.

Statistical analysis

All the data are presented as mean±SD. The level of significance between the two groups was analyzed by Students’ test, more than two groups were assessed by one-way or two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison’s test. Statistical

$$\text{Relative survival rate \%} = [\text{OD}(\text{sample}) - \text{OD}(\text{control}) / \text{OD}(\text{normal}) - \text{OD}(\text{control})] \times 100\%.$$



analysis was performed using SPSS 19.0 (IBM, Chicago, IL, USA). All the results were considered statistically significant at $P < 0.05$.

Results


Phytochemical analysis by LC-MS/MS in BC and ITM

UHPLC-Q Exactive-MS/MS was conducted in both positive and negative ion mode to explore the phytochemical identification of BC and ITM extracts. The retention time, accurate molecular weight, quasi-molecular, formula and MS/MS fragments observed in the positive and negative mode were summarized in Tables 4 and 5. In present study, 40 compounds, including 25 isoflavone glycosides, 5 xanthenes, 1 flavone and 9 other compounds were unambiguously or tentatively identified (Figs. 1, 2). By comparing with authentic standards and MS spectra, 10 compounds, including tectoridin, iristectorin A, iristectorin B, iridin, tectorigenin, iristectorigenin B, iristectorigenin A, irigenin, irisfloreline and dichotomitin were identified definitely, respectively (Additional file 1: Tables S1–S3).

For the MS spectra of isoflavonoid glycosides, the neutral loss of 162 Da was demonstrated as the characteristic

$[M + H - 162]^+$ ion and $[M - H - 162]^-$ of *O*-glycosides such as P4/N9, P5, P6/N14, P7/N19, P8, P9/N20, P10/N21, N11, N15, N16, N22, N24 (Appendix Fig. 9a). Tectorigenin-7-*O*- β -glucosyl (1–6) glucoside and tectorigenin-7-*O*-glucosyl-4'-*O*-glucoside showed loss of 324 Da (-2 glycosides), and generated m/z 301 or 299 ions corresponding to the $[M + H - 2\text{glycosyl}]^+$ or $[M - H - 2\text{glycosyl}]^-$ fragments which was the same as $[M + H]^+$ or $[M - H]^-$ ion of tectorigenin [3]. MS/MS spectra of irigenin showed successive loss of 15 Da, 30 Da and 178 Da, and generated m/z 346, 331 and 183 ions corresponding to the $[M + H - \text{CH}_3]^+$, $[M + H - 2\text{CH}_3]^+$ and $[M + H - \text{C}_{10}\text{H}_{10}\text{O}_3]^+$ fragments. The fragment ion at m/z 183 derived from irigenin Retro-Diels-Alder (RDA) fragmentation, which were observed in all the isoflavones and the most characteristic ion for these isoflavonoids [13]. This RDA fragmentation was shown in Appendix Fig. 9b. By the similar method, other isoflavone aglycones were also characterized.

In this work, five xanthenes including mangiferin, isomangiferin, 7-*O*-methylmangiferin, neomangiferin, 7-*O*-methylisomangiferin were identified in the extracts of BC and ITM. Xanthenes showed $[M + H - 120]^+$ and




[M – H – 120]⁻ fragment ions in MS/MS spectra, which were typical of xanthone C-glucosides [18]. MS/MS spectra of mangiferin showed successive loss of 18 Da and 120 Da, and generated *m/z* 405 and 303 ions corresponding to the [M + H – H₂O]⁺ and [M + H – C₄H₈O₄]⁺ fragments (Appendix Fig. 9c). P2 was tentatively assigned as an isomer of mangiferin, isomangiferin. By the similar method, neomangiferin were characterized. Compounds 7-*O*-methylmangiferin and 7-*O*-methylisomangiferin showed similar fragmentation behaviors as that of mangiferin, thus they could be deduced as derivatives of mangiferin. The [M – H]⁻ ions of 7-*O*-methylmangiferin and 7-*O*-methylisomangiferin were both observed at *m/z* 435, 14 Da more than that of mangiferin. It could be presumed that a hydroxyl group was replaced by a methoxy group in structures of 7-*O*-methylmangiferin and

7-*O*-methylisomangiferin [18]. This fragmentation was shown in Appendix Fig. 9.

BC and ITM in LC-HR/MS metabolomics

PCA was carried out using the resultant data matrix. BC (red circles) and ITM (blue circles) samples were roughly separated on the PC1 (70.2%) vs PC2 (11.5%) plane (Fig. 3A) in positive ion and the PC1 (27.6%) vs PC2 (10.3%) plane (Fig. 3B) in negative ion. Simultaneously, we performed OPLS-DA to search for components that could help to distinguish BC from ITM. The OPLS-DA projection models had a clearer separation of the BC and ITM samples in positive and negative ion (Fig. 3C–D). Furthermore, the s-plot indicated the following characteristic peaks: *m/z* 301.0706 (tectorigenin), *m/z* 463.1232 (tectoridin), *m/z* 361.0912 (irigenin), *m/z* 387.1071 (irisflorentin), *m/z* 331.0798 (iristectorigenin A)



and m/z 331.0796 (iristectorigenin B) (Fig. 4A, B). These remarkable variables of chemical constitute were major phytochemical-marker between BC and ITM (Fig. 4C–H). These components were at the edge of the vertical and horizontal axes, and were explanatory variables that strongly contributed to the objective variable. The multivariate chemometric analysis demonstrated that the remarkable differences of chemical constitute between BC and ITM.

Fingerprint analysis of BC and ITM by DRS study

Optimization of HPLC conditions and method validation

The mobile phase, gradient elution procedures, detection wavelength and flow rates were optimized. The selected chromatographic conditions had satisfactory peak shape and resolution between peaks. Representative chromatograms and spectra were shown in Fig. 5. The peaks were

identified by UV spectra and retention time (Appendix Fig. 8).

Methodological validation experiments were performed on column 14 (Inertsil ODS-3 C₁₈). The precision ($n=6$), stability (48 h, $n=9$), and repeatability ($n=6$) were tested. The results showed that RSD of the peaks t_R and peak areas were both less than 2%, thus meeting the requirements of fingerprint analysis.

Initialization for the DRS method

Details of the operating principle and applications of LCTRS were well documented in previous our literature [10–12]. In brief, the LCTRS method consisted of several steps, including data importing, peak assignment, setting the qualitative chromatographic method.

Table 6 Linear fitting results of actual retention times by LCTRS method for BC and ITM

No.	BC		ITM	
	Calibration curve	R ²	Calibration curve	R ²
Column 1	Y = 1.0425X - 3.9978	0.9995	Y = 1.0285X - 3.4495	0.9991
Column 2	Y = 0.9660X + 2.0604	0.9995	Y = 0.9480X + 2.6624	0.9996
Column 3	Y = 0.9967X - 0.9580	0.9994	Y = 0.9740X + 0.0858	0.9999
Column 4	Y = 0.9985X - 1.4591	0.9989	Y = 0.9686X - 0.3842	0.9994
Column 5	Y = 1.0189X - 4.5116	0.9945	Y = 0.9522X - 1.7815	0.9968
Column 6	Y = 0.9961X + 4.0136	0.9931	Y = 1.0885X + 0.7441	0.9954
Column 7	Y = 1.0128X - 0.3540	0.9997	Y = 1.0260X - 0.9166	0.9997
Column 8	Y = 0.9829X + 1.1290	0.9998	Y = 0.9740X + 1.4514	0.9996
Column 9	Y = 0.9851X + 3.4759	0.9972	Y = 1.0386X + 1.5402	0.9983
Column 10	Y = 1.0075X - 1.0370	0.9999	Y = 0.9978X - 0.6472	0.9999
Column 11	Y = 0.9711X - 1.1506	0.9929	Y = 0.8989X + 1.6232	0.9960
Column 12	Y = 1.0107X - 4.1726	0.9939	Y = 0.93393X - 1.2438	0.9971
Column 13	Y = 0.9632X + 3.0443	0.9997	Y = 0.9688X + 2.8581	0.9994
Column 14	Y = 0.9707X + 5.8023	0.9929	Y = 1.0602X + 2.8936	0.9959
Column 15	Y = 0.9838X + 4.0523	0.9952	Y = 1.0649X + 1.4692	0.9964
Column 16	Y = 1.0038X + 0.5351	0.9985	Y = 1.0407X - 0.8421	0.9987
Column 17	Y = 1.0233X - 2.1767	0.9999	Y = 1.0165X - 2.0256	0.9998
Column 18	Y = 0.9947X + 0.7155	0.9996	Y = 1.0065X + 0.2546	0.9994
Column 19	Y = 1.0340X - 3.6999	0.9995	Y = 1.0217X - 3.1698	0.9991

Table 7 Comparison of different methods (19 columns for method establishment)

Method	Average t _R deviation/min	Identification rate/% (Δt _R ≤ 1.5 min)	Available column amount (Δt _R ≤ 1.5 min)
RRT (BC)	1.07	75.44	8
LCTRS (BC)	0.77	82.89	11
RRT (ITM)	0.72	84.21	10
LCTRS (ITM)	0.45	94.74	13

Optimization and evaluation of DRS method

Retention time prediction by LCTRS method In our study, the St_R values compounds, as a reference value for retention time prediction, were determined by the arithmetic average of the retention times on nineteen columns [10–12]. In *B. chinesis*, we had identified 10 compounds by standard, including tectoridin, iristectorin A, iristectorin B, iridin,

tectorigenin, iristectorigenin B, iristectorigenin A, irigenin, irisfloreline and dichotomitin. Reference compounds selection is very important for the qualitative analysis in the substitute methods. According to DRS method principle, the tectoridin and dichotomitin were selected as two reference compounds for LCTRS method. The actual retention times of the 10 compounds on different columns and chromatographic instruments showed good linear relationships with their St_R (Table 6). Meanwhile, in *I. tectorum*, we also had identified 8 compounds by standard, including tectoridin, iristectorin A, iristectorin B, iridin, tectorigenin, iristectorigenin B, iristectorigenin A and irigenin. The tectoridin and irigenin were selected as two reference compounds for LCTRS method in *I. tectorum*, and the linear fitting results were shown in Table 6.

Retention time prediction by RRT method The RRT method was used the single standard to identify chromatographic peaks. In *B. chinesis*, we selected irigenin as the reference compound because of its appropriate retention time and availability. Meanwhile, in *I. tectorum*, we chose iristectorigenin B as the reference compound. The RRT of ten (BC) and eight (ITM) analytes relative to irigenin and iristectorigenin B were calculated by the arithmetic average of the RRTs on nineteen columns.

Comparison between LCTRS and RRT method To evaluate the advantages and disadvantages of LCTRS and RRT method, we then calculated the absolute deviations (Δt_R) of the actual retention time and predicted retention time on nineteen columns (Additional file 1: Tables S4–S7). As shown in Table 7, the RRT method had a larger average deviation, a lower identification rate and available column amount than LCTRS. The above results showed that LCTRS had a precise, feasible, and superior to identify peaks than RRT.

Sample tests To further verify the reliability of our method LCTRS, we chose SVEA C₁₈ Opal column for sample testing. The detailed procedure of LCTRS method was described in our previous literature [10–12]. In brief, the LCTRS sample tests consisted of three steps, including data integrated, reference compounds assigned and the results obtained. The sample test results were exhibited in Fig. 6, which included the qualitative results of peaks and linear fitting results (Fig. 6).

Toxicity and protective analysis

The cytotoxicity of 8 compounds (0.78–100 μM) and the extracts (25–6400 μg mL⁻¹) was evaluated against HepG2 and A549 cells, respectively (Table 8). Among them, irigenin showed significantly inhibiting activity on the HepG2 cells with IC₅₀ values of 18.66 μM and




Table 8 The toxicity of 8 compounds, BC extracts, ITM extracts and positive drug in HepG2 and A549 cells

Concentration ($\mu\text{M}/\mu\text{g mL}^{-1}$)	HepG2 ($\text{IC}_{50} \pm \text{SD}$)	A549 ($\text{IC}_{50} \pm \text{SD}$)
Oxaliplatin	6.02 \pm 0.23	13.13 \pm 0.16
Tectoridin	135.80 \pm 0.63	83.98 \pm 0.02
Iridin	126.20 \pm 0.07	102.90 \pm 0.50
Tectorigenin	60.28 \pm 0.34	68.44 \pm 0.33
Iristectorigenin B	38.68 \pm 0.28	35.21 \pm 0.22
Iristectorigenin A	44.12 \pm 0.66	42.06 \pm 0.02
Irigenin	18.66 \pm 0.11	47.63 \pm 0.44
Irisflorentine	155.70 \pm 0.17	37.23 \pm 0.28
Dichotomitin	161.80 \pm 0.63	62.01 \pm 0.11
BC extracts	31.41 \pm 0.48	147.40 \pm 0.57
ITM extracts	68.94 \pm 0.12	366.60 \pm 0.56

iristectorigenin B showed significantly inhibiting activity on the A549 cells with IC_{50} values of 35.21 μM (Table 8). Compared with BC extracts, ITM extracts showed strongly inhibitory activity against HepG2 and A549 cells with IC_{50} values of 31.41 $\mu\text{g mL}^{-1}$ and 147.40 $\mu\text{g mL}^{-1}$, respectively (Table 8).

To further investigate their neuroprotective and hepatoprotective, BV2 microglial cells, L02 and BRL-3A cells were treated with 8 compounds and 2 extracts (Additional file 1: Table S8). Results showed that Tectoridin and iridin at concentration of 0.75 μM exhibited higher neuroprotective activity than the positive control, curcumin (Fig. 7A, Additional file 1: Table S8). However, BC extracts and ITM extracts showed no neuroprotective effects on BV2 cells (Fig. 7D–E). Tectoridin and iridin at concentration of 12.5 μM showed more potent hepatoprotective activity than bicyclol (positive control) on L02 cells (Fig. 7B, Additional file 1: Table S8). Compared with BC extracts, ITM extracts showed more potent neuroprotective activity on L02 cells (Fig. 7F, G). Iristectorigenin B, tectoridin and irigenin showed more potent hepatoprotective activity than bicyclol on BRL-3A

cells (Fig. 7C, Additional file 1: Table S8). ITM extracts showed more potent hepatoprotective activity on BRL-3A cells than BC extracts (Fig. 7H, I).

Discussions


In our work, the plant metabolomics, digital reference standard, as well as in vitro activity assay strategy were used to evaluate the chemical constituents, qualities and biological activities of BC and ITM. In the multivariate analysis, the PCA and OPLS-DA score plot indicated the obvious differences in chemical profiling between BC and ITM. Moreover, it showed that 6 principal compounds were successfully identified to contribute to the differences in chemical profiling between BC and ITM.

In digital reference standard study, a series of quality control methods of fingerprints in BC and ITM were developed based on the DRS analyzer, involving the RRT method, LCTRS method. In BC, the tectoridin and dichotomitin were selected as two reference compounds for LCTRS method. In ITM, the tectoridin and irigenin were selected as two reference compounds for LCTRS method. The digital reference standard strategy significantly reduced the analysis cost, saved time and improved the multicomponent analysis efficiency of the analysis method.

In biological activities assay, BC has better anticancer activity than ITM due to its high abundance of irigenin. In contrast, the hepatoprotective activity of ITM was higher than that of BC because of the high abundance of tectoridin. Unfortunately, neither BC nor ITM showed good neuroprotective activity in BV2 cells.

Conclusions

In summary, based on multidimensional strategy, it was indicated that *B. chinensis* and *I. dichotoma* were significantly different in their chemical constituents and biological activities. The results not only showed that these two medicinal plants could not be mixed in clinical medication, but also provided a novel multidimensional strategy for the identification of easily confused, easily adulterated, and even counterfeit medicinal materials.



Appendix

See Figs. 8 and 9.





Fig. 8 Chemical structures and UV spectra. **a** Tectoridin, **b** Iristectorin A, **c** Iristectorin B, **d** Iridin, **e** Tectorigenin, **f** Iristectorigenin B, **g** Iristectorigenin A, **h** Irigenin, **i** Irisflorentine, **j** Dichotomitin



Abbreviations

BC: *Belamcanda chinensis* (L.) DC; ITM: *Iris tectorum* Maxim; DRS: Digital reference standard; RRT: Relative retention time; LCTRS: Linear calibration using two reference substances; TCM: Traditional Chinese medicine; UHPLC-HRMS/MS: Ultra-high-performance liquid chromatography-high resolution tandem mass spectrometry; Me- β -CD: Methyl- β -cyclodextrin; PCA: Principal components analysis; OPLS-DA: Orthogonal partial least squares-discriminant analysis; CCK-8: Cell counting kit-8.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13020-021-00494-3>.

Additional file 1: Table S1. Structures of all isoflavones found in *Belamcanda chinensis* (L.) DC and *Iris tectorum* Maxim. Me: CH_3 , Glu: glucose.

Table S2. Structures of isoflavones from *Belamcanda chinensis* (L.) DC and *Iris tectorum* Maxim with additional dioxolane ring. Me: CH_3 , Glc: glucose.

Table S3. Structures of xanthones from *Belamcanda chinensis* (L.) DC and *Iris tectorum* Maxim with. Me: CH_3 , Glu: glucose. **Table S4.** The absolute deviations (Δt_R) of the actual retention time and predicted retention time on nineteen columns in BC LCTRS method. **Table S5.** The absolute

deviations (Δt_R) of the actual retention time and predicted retention time on nineteen columns in BC RRT method. **Table S6.** The absolute deviations (Δt_R) of the actual retention time and predicted retention time on nineteen columns in ITM LCTRS method. **Table S7.** The absolute deviations (Δt_R) of the actual retention time and predicted retention time on nineteen columns in ITM RRT method. **Table S8.** Neuroprotective and hepatoprotective effects of compounds and positive drug.

Acknowledgements

Not applicable.

Authors' contributions

HXZ, DLM, YZ, SCM, LS conceived and designed the experiments. HXZ, LL, JZ, JMZ, HJS, HL performed the experiments. HXZ, LL analyzed and interpreted the data. HXZ, DLM wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work is supported by the National Natural Science Foundation of China (Grant No. 81573694), and the National Drug Standard Improvement Project in 2021 (General Technology) (Grant No. 2021Z01). The project is also sponsored by "Liaoning BaiQianWan Talents Program in 2018".

Availability of data and materials

All data are fully available without restriction.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China. ²Chongqing Institute for Food and Drug Control, Chongqing 401121, People's Republic of China. ³National Institutes for Food and Drug Control, Beijing 100050, People's Republic of China.

Received: 17 July 2021 Accepted: 10 August 2021

Published online: 26 August 2021

References

1. Woźniak D, Matkowski A. *Belamcandae chinensis* rhizome—a review of phytochemistry and bioactivity. *Fitoterapia*. 2015;107:1–14.
2. Chen Y, Wu CM, Dai RJ, Li L, Yu YH, Li Y, Meng WW, Zhang L, Zhang Y, Deng YL. Combination of HPLC chromatogram and hypoglycemic effect identifies isoflavones as the principal active fraction of *Belamcanda chinensis* leaf extract in diabetes treatment. *J Chromatogr B Anal Technol Biomed Life Sci*. 2011;879:371–8.
3. Xie GY, Zhu Y, Shu P, Qin XY, Wu G, Wang Q, Qin MJ. Phenolic metabolite profiles and antioxidants assay of three Iridaceae medicinal plants for traditional Chinese medicine “She-gan” by on-line HPLC-DAD coupled with chemiluminescence (CL) and ESI-Q-TOF-MS/MS. *J Pharm Biomed Anal*. 2014;98:40–51.
4. Wu C, Li Y, Chen Y, Lao X, Sheng L, Dai R, Meng W, Deng Y. Hypoglycemic effect of *Belamcanda chinensis* leaf extract in normal and STZ-induced diabetic rats and its potential active fraction. *Phytomedicine*. 2011;18:292–7.
5. Ito H, Onoue S, Yoshida T. Isoflavonoids from *Belamcanda chinensis*. *Chem Pharm Bull*. 2001;49:1229–31.
6. Morrissey C, Bektic J, Spengler B, Galvin D, Christoffel V, Klocker H, Fitzpatrick JM, Watson RW. Phytoestrogens derived from *Belamcanda chinensis* have an antiproliferative effect on prostate cancer cells in vitro. *J Urol*. 2004;172:2426–33.
7. Lee HU, Bae EA, Kim DH. Hepatoprotective effect of tectoridin and tectorigenin on *tert*-butyl hyperoxide-induced liver injury. *J Pharmacol Sci*. 2005;97:541–4.
8. Xiong Y, Yang Y, Yang J, Chai H, Li Y, Yang J, Jia Z, Wang Z. Tectoridin, an isoflavone glycoside from the flower of *Pueraria lobata*, prevents acute ethanol-induced liver steatosis in mice. *Toxicology*. 2010;276:64–72.
9. PerezdeSouza L, Alseekh S, Naake T, Fernie A. Mass spectrometry-based untargeted plant metabolomics. *Curr Protoc Plant Biol*. 2019;19(4):e20100.
10. Wang Q, Yu X, Sun L, Tian R, He H, Wang S, Ma S. Fingerprint analysis of phenolic acid extract of *Salvia miltiorrhiza* by digital reference standard analyzer with one or two reference standards. *Chin Med*. 2021;16:8.
11. Sun L, Jin HY, Tian RT, Wang MJ, Liu LN, Ye LP, Zuo TT, Ma SC. A simple method for HPLC retention time prediction: linear calibration using two reference substances. *Chin Med*. 2017;12:16–27.
12. Chen AZ, Sun L, Yuan H, Wu AY, Lu JG, Ma SC. Simultaneous qualitative and quantitative analysis of 11 active compounds in rhubarb using two reference substances by UHPLC. *J Sep Sci*. 2018;41:3686–96.
13. Li J, Li WZ, Huang W, Cheung AW, Bi CW, Duan R, Guo AJ, Dong TT, Tsim KW. Quality evaluation of *Rhizoma Belamcandae* (*Belamcanda chinensis* (L.) DC.) by using high-performance liquid chromatography coupled with diode array detector and mass spectrometry. *J Chromatogr A*. 2009;1216:2071–8.
14. Chen YJ, Liang ZT, Zhu Y, Xie GY, Tian M, Zhao ZZ, Qin MJ. Tissue-specific metabolites profiling and quantitative analyses of flavonoids in the rhizome of *Belamcanda chinensis* by combining laser-microdissection with UHPLC-Q/TOF-MS and UHPLC-QqQ-MS. *Talanta*. 2014;130:585–97.
15. Wen Y, He L, Peng R, Lin Y, Zhao L, Li X, Ye L, Yang J. A novel strategy to evaluate the quality of herbal products based on the chemical profiling, efficacy evaluation and pharmacokinetics. *J Pharm Biomed Anal*. 2018;161:326–35.
16. Jiang H, Yue Q, Zou G, Guoxin LI. Separation of isomer and similar structure compounds in *Belamcandae Rhizoma* by methyl- β -CD chiral mobile phase additive HPLC. *Chin J Mod Appl Pharm*. 2017;34:1–3.
17. Forsberg EM, Huan T, Rinehart D, Benton HP, Warth B, Hilmers B, Siuzdak G. Data processing, multi-omic pathway mapping, and metabolite activity analysis using XCMS online. *Nat Protoc*. 2018;13:633–51.
18. Zhang YY, Wang Q, Qi LW, Qin XY, Qin MJ. Characterization and determination of the major constituents in *Belamcandae Rhizoma* by HPLC-DAD-ESI-MS(n). *J Pharm Biomed Anal*. 2011;56:304–14.
19. Wei Y, Shu P, Hong J, Qin M. Qualitative and quantitative evaluation of phenolic compounds in *Iris dichotoma* Pall. *Phytochem Anal*. 2012;23:197–207.
20. Ito H, Nishitani E, Konoshima T, Takasaki M, Zokuka M, Yoshida T. Flavonoid and benzophenone glycosides from *Coleogyne ramosissima*. *Phytochemistry*. 2000;4:695–700.
21. Ablajan K. A study of characteristic fragmentation of isoflavonoids by using negative ion ESI-MSn. *J Mass Spectrom*. 2011;46:77–84.
22. Liu S, Yan J, Xing J, Song F, Liu Z, Liu S. Characterization of compounds and potential neuraminidase inhibitors from the *n*-butanol extract of compound Indigowoad Root Granule using ultrafiltration and liquid chromatography-tandem mass spectrometry. *J Pharm Biomed Anal*. 2012;59:96–101.
23. Shu P, Hong JL, Gang WU, Yang YB, Qin MJ. Analysis of flavonoids and phenolic acids in *Iris tectorum* by HPLC-DAD-ESI-MS~n. *Chin J Nat Med*. 2010;8:202–7.
24. Duenas M, Hernandez T, Estrella I, Fernandez D. Germination as a process to increase the polyphenol content and antioxidant activity of lupin seeds (*Lupinus angustifolius* L.). *Food Chem*. 2010;117:599–607.
25. Kachlicki P, Einhorn J, Muth D, Kerhoas L, Stobiecki M. Evaluation of glycosylation and malonylation patterns in flavonoid glycosides during LC/MS/MS metabolite profiling. *J Mass Spectrom*. 2008;43:572–86.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.